Eligard Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Thai FDA Category Presentation/Packing

Concise Prescribing Info

Contents

Leuprorelin acetate

Indications/Uses

Hormone dependent advanced prostate cancer & high-risk localized & locally advanced hormone dependent prostate cancer in combination w/ radiotherapy.

Click to view Eligard detailed prescribing information

Dosage/Direction for Use

Adult 22.5-mg inj Single SC inj every 3 mth. 45-mg inj Single SC inj every 6 mth.

Click to view Eligard detailed prescribing information

Overdosage

View Eligard overdosage for action to be taken in the event of an overdose.

Contraindications

Hypersensitivity to leuprorelin acetate & other GnRH agonists. Patients who previously underwent orchiectomy. As sole treatment in prostate cancer patients w/ spinal cord compression or evidence of spinal metastases. Women. Ped patients.

Click to view Eligard detailed prescribing information

Special Precautions

Transient increased serum conc of testosterone, dihydrotestosterone & acid phosphatase during 1st wk of treatment. Closely monitor patients w/ vertebral &/or brain metastases & urinary tract obstruction during 1st few wk of therapy. Decreased bone density, osteoporosis, long lasting testosterone deficiency, increased age, smoking, alcohol consumption, obesity, insufficient exercise; pituitary apoplexy; hyperglycemia, DM; convulsions w/ or w/o history of predisposing factor; ureteral obstruction, spinal cord compression. Increased risk of developing diabetes, MI, sudden cardiac death & stroke. Monitor signs & symptoms of CV disease. Periodically monitor blood glucose &/or HbA1c, ECG & electrolytes. Concomitant use w/ drugs prolonging QT interval. May affect ability to drive & use machines.

Click to view Eligard detailed prescribing information

Use In Pregnancy & Lactation

Click to view Eligard detailed prescribing information

Adverse Reactions

Hot flashes; ecchymoses, erythema; fatigue, inj site burning & paraesthesia. Nasopharyngitis; nausea, diarrhea, gastroenteritis/colitis; pruritus, night sweats; arthralgia, limb pain, myalgia, rigors, weakness; urinary infrequency, difficulty in micturation, dysuria, nocturia, oliguria; breast tenderness, testicular atrophy & pain, infertility, breast hypertrophy, erectile dysfunction, reduced penis size; malaise, inj site pain, bruising & stinging; hematology changes, anaemia; increased blood creatine phosphokinase, prolonged coagulation time.

Click to view Eligard detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Eligard detailed prescribing information

Storage

View Eligard storage conditions for details to ensure optimal shelf-life.

Description

View Eligard description for details of the chemical structure and excipients (inactive components).

Action

View Eligard mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Cancer Hormone Therapy / Trophic Hormones & Related Synthetic Drugs

ATC Classification

L02AE02 - leuprorelin ; Belongs to the class of gonadotropin releasing hormone analogues. Used in endocrine therapy.

Thai FDA Category

Presentation/Packing

Form

Eligard powd for inj 22.5 mg

Packing/Price

1's

Form

Eligard powd for inj 45 mg

Packing/Price

1's

Eligard

leuprorelin

Manufacturer:

Tolmar

Distributor:

DCH Auriga